CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD • US21900C3088

7.21 USD
+0.08 (+1.12%)
At close: Mar 2, 2026
7.21 USD
0 (0%)
After Hours: 3/2/2026, 4:30:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall CRMD gets a fundamental rating of 6 out of 10. We evaluated CRMD against 193 industry peers in the Pharmaceuticals industry. CRMD has only an average score on both its financial health and profitability. CRMD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make CRMD a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year CRMD was profitable.
  • In the past year CRMD had a positive cash flow from operations.
  • CRMD had negative earnings in each of the past 5 years.
  • CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • With an excellent Return On Assets value of 21.64%, CRMD belongs to the best of the industry, outperforming 97.93% of the companies in the same industry.
  • With an excellent Return On Equity value of 43.43%, CRMD belongs to the best of the industry, outperforming 97.93% of the companies in the same industry.
  • CRMD has a Return On Invested Capital of 13.31%. This is amongst the best in the industry. CRMD outperforms 92.75% of its industry peers.
Industry RankSector Rank
ROA 21.64%
ROE 43.43%
ROIC 13.31%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • CRMD's Profit Margin of 75.83% is amongst the best of the industry. CRMD outperforms 98.45% of its industry peers.
  • CRMD has a better Operating Margin (48.51%) than 98.96% of its industry peers.
  • CRMD has a better Gross Margin (92.61%) than 94.30% of its industry peers.
  • In the last couple of years the Gross Margin of CRMD has grown nicely.
Industry RankSector Rank
OM 48.51%
PM (TTM) 75.83%
GM 92.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CRMD is creating some value.
  • Compared to 1 year ago, CRMD has more shares outstanding
  • CRMD has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 1.48, we must say that CRMD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.48, CRMD is in line with its industry, outperforming 59.07% of the companies in the same industry.
  • The Debt to FCF ratio of CRMD is 1.96, which is an excellent value as it means it would take CRMD, only 1.96 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.96, CRMD belongs to the top of the industry, outperforming 95.34% of the companies in the same industry.
  • CRMD has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
  • CRMD's Debt to Equity ratio of 0.39 is in line compared to the rest of the industry. CRMD outperforms 40.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 1.96
Altman-Z 1.48
ROIC/WACC1.46
WACC9.09%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • CRMD has a Current Ratio of 1.94. This is a normal value and indicates that CRMD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CRMD (1.94) is worse than 61.14% of its industry peers.
  • A Quick Ratio of 1.73 indicates that CRMD should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.73, CRMD is in line with its industry, outperforming 43.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.73
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • CRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.32%, which is quite impressive.
  • CRMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 1647.68%.
  • The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
Revenue 1Y (TTM)1647.68%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%

3.2 Future

  • The Earnings Per Share is expected to grow by 50.97% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 60.62% on average per year.
EPS Next Y939.53%
EPS Next 2Y163.26%
EPS Next 3Y81.97%
EPS Next 5Y50.97%
Revenue Next Year683.98%
Revenue Next 2Y179.47%
Revenue Next 3Y93.32%
Revenue Next 5Y60.62%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M 800M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

10

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 3.50 indicates a rather cheap valuation of CRMD.
  • Compared to the rest of the industry, the Price/Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 97.41% of the companies listed in the same industry.
  • CRMD is valuated cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 4.43, the valuation of CRMD can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, CRMD is valued cheaply inside the industry as 96.89% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, CRMD is valued rather cheaply.
Industry RankSector Rank
PE 3.5
Fwd PE 4.43
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 95.85% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CRMD is valued cheaper than 94.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.63
EV/EBITDA 5.96
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of CRMD may justify a higher PE ratio.
  • A more expensive valuation may be justified as CRMD's earnings are expected to grow with 81.97% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y163.26%
EPS Next 3Y81.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORMEDIX INC

NASDAQ:CRMD (3/2/2026, 4:30:01 PM)

After market: 7.21 0 (0%)

7.21

+0.08 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners61.7%
Inst Owner Change0.75%
Ins Owners7%
Ins Owner Change11.77%
Market Cap568.08M
Revenue(TTM)214.30M
Net Income(TTM)162.50M
Analysts83.08
Price Target15.15 (110.12%)
Short Float %22.54%
Short Ratio5.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)75.14%
Min EPS beat(2)58.8%
Max EPS beat(2)91.47%
EPS beat(4)4
Avg EPS beat(4)54.36%
Min EPS beat(4)13.12%
Max EPS beat(4)91.47%
EPS beat(8)7
Avg EPS beat(8)32.13%
EPS beat(12)8
Avg EPS beat(12)21.06%
EPS beat(16)12
Avg EPS beat(16)20.34%
Revenue beat(2)2
Avg Revenue beat(2)16.66%
Min Revenue beat(2)14.48%
Max Revenue beat(2)18.84%
Revenue beat(4)4
Avg Revenue beat(4)13.08%
Min Revenue beat(4)3.69%
Max Revenue beat(4)18.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.86%
PT rev (3m)-21.8%
EPS NQ rev (1m)-2.39%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0.05%
EPS NY rev (3m)30.74%
Revenue NQ rev (1m)-1.6%
Revenue NQ rev (3m)-0.39%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)9.31%
Valuation
Industry RankSector Rank
PE 3.5
Fwd PE 4.43
P/S 2.65
P/FCF 7.63
P/OCF 7.58
P/B 1.52
P/tB N/A
EV/EBITDA 5.96
EPS(TTM)2.06
EY28.57%
EPS(NY)1.63
Fwd EY22.57%
FCF(TTM)0.94
FCFY13.1%
OCF(TTM)0.95
OCFY13.2%
SpS2.72
BVpS4.75
TBVpS-0.42
PEG (NY)0
PEG (5Y)N/A
Graham Number14.84
Profitability
Industry RankSector Rank
ROA 21.64%
ROE 43.43%
ROCE 16.84%
ROIC 13.31%
ROICexc 14.63%
ROICexgc 53.33%
OM 48.51%
PM (TTM) 75.83%
GM 92.61%
FCFM 34.73%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 1.96
Debt/EBITDA 1.34
Cap/Depr 12.94%
Cap/Sales 0.26%
Interest Coverage 3893.29
Cash Conversion 69.29%
Profit Quality 45.8%
Current Ratio 1.94
Quick Ratio 1.73
Altman-Z 1.48
F-Score5
WACC9.09%
ROIC/WACC1.46
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
EPS Next Y939.53%
EPS Next 2Y163.26%
EPS Next 3Y81.97%
EPS Next 5Y50.97%
Revenue 1Y (TTM)1647.68%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%
Revenue Next Year683.98%
Revenue Next 2Y179.47%
Revenue Next 3Y93.32%
Revenue Next 5Y60.62%
EBIT growth 1Y303.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year880.06%
EBIT Next 3Y83.07%
EBIT Next 5YN/A
FCF growth 1Y319.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y321.67%
OCF growth 3YN/A
OCF growth 5YN/A

CORMEDIX INC / CRMD FAQ

What is the fundamental rating for CRMD stock?

ChartMill assigns a fundamental rating of 6 / 10 to CRMD.


What is the valuation status for CRMD stock?

ChartMill assigns a valuation rating of 10 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.


Can you provide the profitability details for CORMEDIX INC?

CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.


What is the valuation of CORMEDIX INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CORMEDIX INC (CRMD) is 3.5 and the Price/Book (PB) ratio is 1.52.


What is the financial health of CORMEDIX INC (CRMD) stock?

The financial health rating of CORMEDIX INC (CRMD) is 5 / 10.